AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$FLNA

Barry Richard purchased $78K of FLNA (indirect holdings)

Barry Richard (President & CEO) purchased 93,091 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.84 on 2026-09-28.

Original reporting
SEC EDGAR · Barry Richard
Published Sep 30, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FLNA
Bullish
medium confidence
Mentioned
$FLNA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FLNABullishLow
01

Why it matters

The filing provides fresh insider buying data, but the transaction size is modest, limiting immediate market impact.

02

Market read

New insider purchase adds a small positive signal for FLNA, unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical milestones not disclosed could amplify significance of insider activity.

Relevance 4/10Novelty 4/10Timing: filing posted after market close on 2026-09-30

Background

Filana Therapeutics filed a Form 4 showing a $78K purchase by its CEO, a standard regulatory disclosure.

Company-level read

Ticker impact

$FLNABullishMedium confidence
Context

Form 4 disclosed President & CEO Barry Richard bought 93,091 shares for $78,196, increasing his stake to over 1M shares.

Expected impact

likely slight upward pressure as market prices in insider confidence

Evidence & confidence

Purchase size is modest ($78K) but insider is CEO; market may view as a positive signal.

Market effects

Sector

Minimal impact on biotech sector; insider activity is routine.

Regional

No regional effect.

Global

Limited to investors tracking Filana Therapeutics.

Counterpoint

What could challenge this read

Small insider buy may be insignificant; price could remain unchanged.

Key entities

  • person
    Barry Richard

    President & CEO of Filana Therapeutics, insider purchaser.

  • company
    Filana Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker FLNA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FLNA insider trading history →

Related articles

SEP 22
$FLNAMedAI 8/10

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio

SEC EDGAR 8-K2 min
JUL 29
$FLNAMed

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing

SEC EDGAR 8-K4 min